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Abstract: Brain is a lipid-rich tissue, and fatty acids (FAs) play a crucial role in brain function,
including neuronal cell growth and development. This study used GC-MS to survey all detectable
FAs in the human parietal cortex (Brodmann area 7). These FAs were accurately quantified in 27
cognitively normal age-matched controls, 16 cases of moderate Alzheimer’s disease (AD), 30 severe
AD, and 14 dementia with Lewy bodies (DLB). A total of 24 FA species were identified. Multiple
comparison procedures, using stepdown permutation tests, noted higher levels of 13 FAs but the
majority of changes were in moderate AD and DLB, rather than severe AD. Subjects with moderate
AD and DLB pathology exhibited significantly higher levels of a number of FAs (13 FAs and
12 FAs, respectively). These included nervonic, lignoceric, cis-13,16-docosadienoic, arachidonic,
cis-11,14,17-eicosatrienoic, erucic, behenic, α-linolenic, stearic, oleic, cis-10-heptanoic, and palmitic
acids. The similarities between moderate AD and DLB were quite striking—arachidic acid was the
only FA which was higher in moderate AD than control, and was not similarly affected in DLB.
Furthermore, there were no significant differences between moderate AD and DLB. The associations
between each FA and a number of variables, including diagnosis, age, gender, Aβ plaque load, tau
load, and frontal tissue pH, were also investigated. To conclude, the development of AD or DLB
pathology affects brain FA composition but, intriguingly, moderate AD neuropathology impacts
this to a much greater extent. Post-mortem delay is a potential confounding factor, but the findings
here suggest that there could be a more dynamic metabolic response in the earlier stages of the
disease pathology.
Keywords: fatty acid; GC-MS; Alzheimer’s disease; dementia with Lewy bodies;
metabolomics; lipidomics
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1. Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive memory
loss and deteriorating cognitive abilities in older populations. Dementia currently affects around
820,000 people in the United Kingdom, and the estimated cost of the condition to the economy is
£24 billion per annum [1]. Global projections suggest that the number of people affected by AD will
triple to 115 million by the year 2050 [1]. The main pathological hallmarks of AD are the accumulation
of β-amyloid plaques and neurofibrillary tangles [2,3]. There has been a concerted effort to investigate
these two histological features, but the exact causes and pathological consequences of AD remain to
be elucidated.
Metabolomics is the investigation of small, often chemically diverse molecules, including lipids,
saccharides, steroids, bile acids, and amino acids [4,5]. Lipidomics is a subdiscipline of metabolomics
focusing entirely on the measurement of lipid and lipid-like molecules. Profiling of the lipidome
has revealed alterations in (i) lipid metabolism [4,6,7]; (ii) lipid-mediated signaling processes [4,8,9];
and (iii) biochemical interactions with other lipids, proteins, and metabolites [10,11]. Ultimately,
these techniques could lead to new discoveries in terms of disease pathogenesis and pharmacological
targets [12,13]. Lipid profiling techniques are increasingly being employed in AD in the hope that
they might provide new mechanistic insights or novel diagnostic biomarkers [4]. The most common
approach has been the profiling of fatty acids (FAs) by either GC-MS or LC-MS. There are clear reasons
for applying precise lipid profiling techniques in an AD context. The brain is one of the most lipid-rich
tissues in the human body [14] and, also, the earliest reports of AD pathology noted the occurrence
of “fat inclusions” or “lipid granules” in the brain. Around 50% of neuronal cell membranes are
composed of fatty acids (FA) that are polyunsaturated [15]. These FAs appear to be incorporated into
membrane phospholipids and secondary signaling messengers, which modulate oxidative stress and
inflammatory processes in neurons [15].
It is surprising that FA profiling techniques have shown relatively subtle changes in brain FA
composition [16]. This, in part, can be attributed to current technical limitations, which makes it
difficult to detect changes in the subcellular distribution of FAs. However, it is clear that the brain
concentrations of a small number of FAs are affected by the development of AD pathology [16].
Altered levels of stearic acid, arachidonic acid, and oleic acid have been observed in the frontal and
temporal cortex of human cases of AD [16]. This investigation also showed that the parietal cortex
is comparably much less affected [16]. Currently, it is a major challenge to distinguish between FA
alterations that are secondary to the development of AD, and those that which may contribute to the
disease process. Progress in this area is hampered by the fact that most studies (including our own)
have not specifically determined how the severity of AD pathology affects the FA profile [12,13,16,17].
There is a need for more research in this area. Recent metabolomic studies profiling APP/PS1 mice
found that metabolites, including many lipid species, are affected by the development of AD pathology.
However, the disturbances are transient in nature, not occurring in either a persistent or progressive
manner [18]. Lipid disturbances in both brain and plasma appear to be highly dependent on the
disease stage/severity, and many lipids differ much less in the later stages of the pathology [18].
This study investigated how exactly human brain FA profiles are affected by the extent of
neuropathological change. The parietal cortex was selected because it is not the primary site of
AD pathology and, also, because FA composition is largely unaffected in AD. We used a fatty acid
methyl ester (FAME) methodology to survey all detectable FA species present in this brain region.
A quantitative method was established for 24 of these. A full range of analytical FAME standards and
internal standards were employed to quantify FAs in pathologically and clinically confirmed cases of
AD and dementia with Lewy bodies (DLB), in addition to normal age-matched control cases. To assess
the influence of AD severity on FAs, the cases of AD were classified as either moderate (“intermediate”
AD neuropathological change, Braak tangle stage III–IV) or severe (“high” AD neuropathological
change, Braak tangle stage V–VI).
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2. Results
Initial survey of the FA composition of human post-mortem parietal cortex identified 24
quantifiable (calibration curves for FAMEs with R2 values of <0.98 were deemed inadmissible)
individual FAME peaks that were consistently present in all subject groups. The potential for
there to be differences between subject groups was immediately evident from relative peak intensity
data. FAME peak identities were assigned by mass spectrometry and subsequently confirmed using
FAME analytical standards. Typical total ion chromatograms (TICs) for specimens from cases of
moderate and severe AD, DLB, and age-matched control subjects, are shown in Figure 1. Initially
the Kruskal–Wallis test was used to shortlist those FAs presenting at least one statistically significant
difference between any of the 4 subgroups (p < 0.05; FDR < 0.05) (Table 1). A total of 13 FAs differed,
including (i) 4 saturated FAs: lignoceric acid (C24:0), behenic acid (C22:0), arachidic acid (C20:0), and
stearic acid (C18:0); (ii) 5 monounsaturated FAs: nervonic acid (C24:1∆15), oleic acid (c-C18:1∆9),
cis-10-heptadecanoic acid (C17:1∆10), palmitic (c-C18:1∆9), and erucic acid (C22:1∆130); and (iii)
4 polyunsaturated FAs; cis-13,16-docosadienoic acid (C22:2∆13,16), arachidonic acid (C20:4∆5,8,11,14),
cis-11,14,17-eicosatrienoic acid (C20:3∆11,14,17), and α-linolenic acid (C18:3∆9,12,15) (Table 1).
Multiple comparison procedures using stepdown permutation p-values, on the ranked data, were
used to investigate the nature of group differences for variables, with a false discovery rate of 0.05 or
less (Table 2). This revealed that only one FA (oleic acid (c-C18:1∆9)) significantly differed between
severe AD and control samples (Table 2). Contrastingly, a total of 12 and 13 FAs were significantly
(p < 0.05) elevated in DLB and moderate AD, respectively, compared with control. The levels of 5 FAs
differed between severe AD and DLB: arachidonic acid (C20:4∆5,8,11,14), cis-11,14,17-eicosatrienoic
acid (C20:3∆11,14,17), erucic acid (C22:1∆130), behenic acid (C22:0), and linolenic acid (C18:3∆9,12,15)
(Table 2). The profile of moderate and severe AD samples differed markedly, with 9 FAs being
significantly lower in severe AD (Figure 2). Significant differences were found for Total FA, Total
SFA, Total monounsaturated FA (MUFA), Total polyunsaturated FA (PUFA), but not for either Omega
3/Omega 6 ratio or 16:1/16:0 ratio (Table S2). No significant associations were detected between any
FA and the subject age, frontal tissue pH, and beta-amyloid levels (Table S3). Only linoleic acid differed
between male and female subjects (41% higher in females). Six FAs (lignoceric acid, arachidonic acid,
cis-11,14,17-eicosatrienoic acid, linolenic acid, arachidic acid, and stearic acid) negatively correlated
with post-mortem delay. Three FAs (cis-11,14,17-eicosatrienoic acid, erucic acid, and linoelaidic acid)
negatively correlated with levels of tau protein.
The scores plot generated by unsupervised principal component analysis (PCA) showed only very
weak separation between the 4 groups (Figure S1). The PCA results showed that the first component
(PC1) explained 36.3% of the variation. Although there was overlap among the 4 groups, it was
noteworthy that moderate AD and DLB cases were distributed at the extreme end of PC1.
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acid, 16. erucic acid, 17. cis-11,14,17-eicosatrienoic acid, 18. cis-11,14-eicosadienoic acid, 19. behenic acid, 20. arachidonic acid, 21. tricosanoic acid, 22. cis-13,16-
docosadienoic acid, 23. lignoceric acid, 24. nervonic acid, 25. docosahexaenoic acid. 
Figure 1. GC-MS detection of brain fatty acids. A typical total ion chromatogram (TIC) of fatty acid methyl esters (FAMEs) from post-mortem brain tissue. The peaks
were identified as 1. lauric acid, 2. pentadecanoic acid, 3. palmitic acid, 4. palmitoleic acid, 5. heptadecanoic acid, 6. cis-10-heptadecanoic acid, 7. stearic acid, 8. oleic
acid, 9. linolelaidic acid, 10. linoleic acid, 11. arachidic acid, 12. cis-11-eicosanoic acid, 13. linolenic acid, 14. heneicosanoic acid, 15. cis-8,11,14-eicosatrienoic acid,
16. erucic acid, 17. cis-11,14,17-eicosatrienoic acid, 18. cis-11,14-eicosadienoic acid, 19. behenic acid, 20. arachidonic acid, 21. tricosanoic acid, 22. cis-13,16-docosadienoic
acid, 23. lignoceric acid, 24. nervonic acid, 25. docosahexaenoic acid.
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Table 1. Fatty acid measurements in post-mortem brain samples of Brodmann 7 region from control, moderate stage AD, full/late stage AD, and DLB subjects.
FA concentrations (g/kg dry weight) displayed as mean ± standard deviation (SD), 1st Quartile (Q1), median, and 3rd Quartile (Q3). The adjusted false discovery rate
(FDR) value of p < 0.05 generated from the Kruskal–Wallis (KW) tests was deemed to be significant. Total FA was calculated based on all 24 measured FAs.
Fatty Acid Control Moderate AD
Name Lipid No. RT Mass Mean± SD Q1 Median Q3 Mean± SD Q1 Median Q3
Docosahexanoic Acid C22:6∆4,7,10,13,16,19 45.01 342.51 24.77 ± 6.695 18.830 24.640 30.200 30.184 ± 4.215 27.600 28.540 33.130
Nervonic Acid C24:1∆15 40.68 380.65 3.925 ± 1.527 3.331 3.686 5.014 5.517 ± 2.549 4.795 5.706 7.311
Lignoceric Acid C24:0 39.55 382.66 0.767 ± 0.317 0.657 0.756 0.851 1.187 ± 0.256 1.003 1.126 1.404
cis-13,16-Docosadienoic acid C22:2∆13,16 38.89 350.58 0.103 ± 0.052 0.065 0.091 0.125 0.146 ± 0.044 0.122 0.156 0.178
Arachidonic acid C20:4∆5,8,11,14 38.08 318.49 10.81 ± 3.309 8.280 10.270 13.600 14.04 ± 1.244 12.950 14.480 15.050
Tricosanoic Acid C23:0 37.42 368.64 0.165 ± 0.140 0.024 0.138 0.248 0.218 ± 0.207 0.014 0.285 0.417
cis-11,14,17-Eicosatrienoic acid C20:3∆11,14,17 28.93 320.51 0.565 ± 0.292 0.322 0.656 0.807 1.098 ± 0.242 0.937 1.139 1.294
Erucic acid C22:1∆13 35.60 352.59 0.409 ± 0.188 0.260 0.427 0.514 0.627 ± 0.145 0.539 0.653 0.720
cis-8,11,14-Eicosatreinoic acid C20:3∆8,11,14 37.05 320.51 1.010 ± 0.389 0.729 1.031 1.245 1.253 ± 0.523 1.262 1.295 1.519
Behenic acid C22:0 35.18 354.61 0.160 ± 0.085 0.095 0.177 0.211 0.273 ± 0.060 0.222 0.258 0.323
cis-11,14-Eicosadienoic acid C20:2 ∆11,14 35.18 308.50 0.549 ± 0.482 0.253 0.357 0.629 0.534 ± 0.411 0.242 0.449 0.648
Heneicosanoic acid C21:0 34.39 340.58 0.018 ± 0.007 0.011 0.020 0.024 0.026 ± 0.009 0.022 0.026 0.030
Linolenic acid C18:3∆9,12,15 34.20 294.26 3.514 ± 1.315 2.469 4.067 4.613 5.401 ± 1.048 4.564 5.209 6.059
cis-11-Eicosanoic acid C20:1 ∆11 33.45 310.50 2.010 ± 0.803 1.539 2.016 2.597 2.616 ± 1.266 2.075 2.905 3.513
Arachidic acid C20:0 32.85 326.56 0.200 ± 0.070 0.165 0.216 0.247 0.292 ± 0.047 0.259 0.288 0.315
Linoleic acid c-C18:2∆9,12 32.38 294.47 0.702 ± 0.478 0.386 0.777 1.012 0.941 ± 0.593 0.751 0.989 1.327
Linolelaidic acid t-C18:2∆9,12 31.29 294.47 0.019 ± 0.009 0.012 0.016 0.024 0.023 ± 0.011 0.014 0.023 0.029
Oleic acid c-C18:1∆9 30.82 297.49 22.92 ± 6.249 19.400 23.560 27.370 30.664 ± 4.219 27.490 29.960 33.460
Stearic acid C18:0 29.79 298.50 20.37 ± 5.037 15.730 21.290 23.950 25.985 ± 2.407 24.770 26.170 26.770
cis-10-Heptadecanoic acid C17:1∆10 29.30 284.48 2.275 ± 0.918 1.720 2.144 2.537 3.054 ± 0.485 2.631 2.965 3.532
Heptadecanoic acid C17:0 28.21 283.48 0.308 ± 0.104 0.254 0.300 0.366 0.366 ± 0.035 0.344 0.372 0.396
Palmitoleic acid C16:1∆9 27.77 270.45 0.842 ± 0.322 0.653 0.790 1.062 1.046 ± 0.221 0.928 1.113 1.186
Palmitic acid C16:0 26.60 270.45 18.09 ± 4.308 14.450 18.110 21.500 22.670 ± 1.848 21.080 22.680 23.820
Pentadecanoic acid C15:0 24.91 256.42 0.159 ± 0.061 0.118 0.165 0.184 0.174 ± 0.028 0.154 0.184 0.192
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Fatty Acid Severe AD DLB p-Value
Name Lipid No. RT Mass Mean± SD Q1 Median Q3 Mean± SD Q1 Median Q3 KW FDR
Docosahexanoic Acid C22:6∆4,7,10,13,16,19 45.01 342.51 27.694 ± 9.311 20.090 26.970 34.740 32.329 ± 9.102 26.010 31.960 36.140 0.0328 0.0525
Nervonic Acid C24:1∆15 40.68 380.65 4.352 ± 2.385 2.747 4.633 5.775 5.348 ± 2.763 4.417 5.547 6.530 DLB 0.0251
Lignoceric Acid C24:0 39.55 382.66 0.942 ± 0.442 0.576 0.924 1.125 1.023 ± 2.384 0.846 0.990 1.243 0.0009 0.0027
cis-13,16-Docosadienoic acid C22:2∆13,16 38.89 350.58 0.116 ± 0.059 0.084 0.102 0.140 0.144 ± 0.049 0.114 0.129 0.161 0.0014 0.0034
Arachidonic acid C20:4∆5,8,11,14 38.08 318.49 10.83 ± 4.169 7.929 10.660 13.790 14.43 ± 5.755 12.040 14.930 16.070 0.0008 0.0027
Tricosanoic Acid C23:0 37.42 368.64 0.219 ± 0.154 0.139 0.209 0.336 0.238 ± 3.177 0.011 0.292 0.391 0.5651 0.5651
cis-11,14,17-Eicosatrienoic acid C20:3∆11,14,17 28.93 320.51 0.684 ± 0.508 0.299 0.527 1.008 1.105 ± 7.267 0.942 1.042 1.267 0.0001 0.0006
Erucic acid C22:1∆13 35.60 352.59 0.421 ± 0.217 0.276 0.429 0.559 0.633 ± 5.170 0.517 0.636 0.707 0.0001 0.0006
cis-8,11,14-eicosatreinoic acid C20:3∆8,11,14 37.05 320.51 1.193 ± 0.371 0.990 1.227 1.419 1.211 ± 4.636 0.969 1.176 1.531 0.0535 0.0755
Behenic acid C22:0 35.18 354.61 0.202 ± 0.098 0.142 0.207 0.266 0.258 ± 8.088 0.213 0.255 0.325 0.0001 0.0006
cis-11,14-eicosadienoic acid C20:2 ∆11,14 35.18 308.50 0.687 ± 0.629 0.222 0.429 1.083 0.856 ± 9.508 0.435 0.859 1.369 0.2064 0.2431
Heneicosanoic acid C21:0 34.39 340.58 0.021 ± 0.008 0.015 0.021 0.026 0.023 ± 8.009 0.017 0.024 0.028 0.0312 0.0525
Linolenic acid C18:3∆9,12,15 34.20 294.26 3.954 ± 1.650 2.722 3.979 4.928 5.195 ± 9.834 4.679 5.519 5.528 0.0001 0.0006
cis-11-Eicosanoic acid C20:1 ∆11 33.45 310.50 1.842 ± 1.316 0.377 1.975 2.640 2.137 ± 2.357 1.123 2.669 2.845 0.1439 0.1919
Arachidic acid C20:0 32.85 326.56 0.224 ± 0.079 0.169 0.239 0.266 0.250 ± 9.088 0.216 0.257 0.287 0.0005 0.0020
Linoleic acid c-C18:2∆9,12 32.38 294.47 0.641 ± 0.576 0.016 0.743 0.988 0.720 ± 9.747 0.020 0.730 1.283 0.3740 0.3903
Linolelaidic acid t-C18:2∆9,12 31.29 294.47 0.017 ± 0.010 0.011 0.041 0.019 0.021 ± 1.009 0.013 0.020 0.028 0.2111 0.2413
Oleic acid c-C18:1∆9 30.82 297.49 26.416 ± 8.524 21.350 28.260 32.480 30.818 ± 8.451 28.110 29.720 31.870 0.0003 0.0014
Stearic acid C18:0 29.79 298.50 22.679 ± 5.695 17.820 23.630 25.710 25.708 ± 6.692 23.420 24.240 25.580 0.0011 0.0029
cis-10-Heptadecanoic acid C17:1∆10 29.30 284.48 2.932 ± 1.470 1.874 2.621 3.898 3.177 ± 5.925 2.671 2.826 3.444 0.0021 0.0046
Heptadecanoic acid C17:0 28.21 283.48 0.320 ± 0.094 0.248 0.321 0.397 0.375 ± 5.073 0.333 0.366 0.386 0.0448 0.0672
Palmitoleic acid C16:1∆9 27.77 270.45 0.855 ± 0.409 0.647 0.895 1.098 0.760 ± 1.489 0.289 0.722 1.282 0.1736 0.2193
Palmitic acid C16:0 26.60 270.45 20.953 ± 5.023 17.150 21.220 23.920 22.929 ± 7.392 20.150 22.230 24.660 0.0036 0.0072
Pentadecanoic acid C15:0 24.91 256.42 0.165 ± 0.051 0.133 0.163 0.199 0.187 ± 3.048 0.152 0.173 0.223 0.2345 0.2558
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Table 2. Fatty acids significantly higher in post-mortem brain tissue from subjects with moderate AD, severe AD, or DLB pathology. Following the Kruskal–Wallis
tests, multiple comparison procedures using stepdown permutation p-values on the ranked data were used to investigate the nature of group differences for variables
with a false discovery rate of 0.05 or less.
Fatty Acid
p-Values
Control vs.
Moderate AD
Control vs.
Severe AD
Control vs.
DLB
Moderate AD vs.
Severe AD
Moderate AD
vs. DLB
Severe AD vs.
DLB
Nervonic acid (mono) 0.0453 0.7397 0.0453 0.1811 0.9578 0.1811
Erucic acid (mono) 0.0011 1 0.0011 0.0022 1 0.0022
Oleic acid (mono) 0.0006 0.0337 0.0011 0.1912 0.8664 0.1917
cis-10-Heptanoic acid (mono) 0.0049 0.0899 0.0068 0.3476 0.8887 0.3476
cis-13,16-Docosadienoic acid (poly) 0.0036 0.5416 0.0104 0.0331 0.7307 0.0707
Arachidonic acid (poly) 0.0094 1 0.0094 0.0128 1 0.0128
cis-11,14,17-Eicosatrienoic acid (poly) 0.0001 0.4203 0.0001 0.0004 0.9930 0.0004
Linolenic acid (poly) 0.0003 0.6126 0.0004 0.0029 0.8786 0.0039
Lignoceric acid (saturated) 0.0004 0.1263 0.0333 0.0514 0.4317 0.4317
Behenic acid (saturated) 0.0002 0.1151 0.0006 0.0186 0.7104 0.0455
Arachidic acid (saturated) 0.0001 0.3774 0.0783 0.0046 0.2069 0.3774
Stearic acid (saturated) 0.0006 0.2969 0.0344 0.0344 0.3416 0.3416
Palmitic acid (saturated) 0.0065 0.0902 0.0143 0.4114 0.7813 0.4832
Number of FAs significantly different 13 1 12 9 0 5
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3. Discussion
This study accurately quantified the FA composition of post-mortem human brain tissue from
87 subjects: control subjects (n = 27); moderate AD (n = 16), severe AD (n = 30), and DLB (n = 14).
A key strength of this study is its focused approach to brain FA measurements. It represents the widest
brain FA coverage measured, thus far, in AD or other forms of dementia. Previous studies have found
gender-related differences in brain FA content in AD [12], but this was not evident in the present study.
Other studies typically measure a much narrower range of FAs, of perhaps 14 or 16 FAs at most [16,19].
We compared the measured brain FA levels as percentage % of total FA content, and found them to be
broadly comparable with a number of other studies [16,17,20–26]. In general, the findings indicate that,
in parietal cortex, there is a trend for higher FA levels in moderate AD, but not in cases of severe AD.
Several FAs where significantly affected, including lignoceric acid, cis-13,16-docosadienoic, arachidonic
acid, cis-11,14,17-eicosatrienoic acid, erucic acid, linolenic acid, and stearic acid. This is not the first
time that FA concentrations have been shown to be higher in AD [20], however, these earlier changes
suggest mechanisms involving lipid metabolism in response to the development of disease pathology.
It has previously been suggested that the relatively higher brain FA content may be due to ceramide
accumulation due to the activation of sphingomyelinase in oligodendrocytes, induced by increases in
amyloid beta peptide levels [20].
A particular limitation of the present study was that post-mortem delay was significantly longer
in cases of severe AD, compared with cases of moderate AD. In general, the post-mortem delay
durations for the brain specimens obtained were relatively long. In our tissue requests, we did our
best to obtain samples with as short a delay as possible, to minimize tissue degradation/oxidation
which, in turn, could affect the FA composition. Where possible, we attempted to match groups as
much as possible with respect to post-mortem delay. This was performed within the constraints of
the available tissue with the appropriate pathological characteristics. It is possible that post-mortem
delay is a confounding factor which explains significant differences for some FAs between Severe
and Moderate AD groups. An in-depth analysis finds that there is some support for this—there were
modest but significant associations between the duration of post-mortem delay and concentrations
of six individual FAs. All of these were negative associations, suggesting that longer post-mortem
delay may decrease these FAs. Five of the six FAs where among the 13 shortlisted as differing between
groups. Furthermore, it is also clear that there were group differences as far as aggregated FA levels
are concerned (total FA, total saturated, total monounsaturated, or total polyunsaturated). For this
reason, the findings here should be interpreted with a degree of care because post-mortem delay is an
uncontrolled variable.
Nervonic acid is a product of the desaturation and elongation processes of several fatty acids,
including palmitic acid, stearic acid, and oleic acid. Through the action of stearoyl CoA desaturase
(SCD) enzyme, these fatty acids undergo a series of elongation steps prior to the production of nervonic
acid. Higher concentrations of these fatty acids, in moderate AD pathology, could be attributed to
the increased activity of SCD itself. A recent study has demonstrated that nervonic acid and several
mono-unsaturated fatty acids produced by SCD are markedly upregulated in brain samples of AD
patients [27]. Higher FA levels and SCD activity have been shown to correlate closely with cognitive
impairment [27]. Although our findings contrast with that of Astarita et al. [27], SCD activity does
provide a potential pathogenic mechanism.
Higher palmitic acid concentrations in moderate AD pathology indicate damaging effects on the
brain. Palmitic acid has been shown to induce tau hyperphosphorylation and to elevate β-secretase
activity in embryonic rat cortex cultures [28]. Furthermore, the trend for palmitic acid is in keeping
with the plasma levels observed in another study [19]. The case is also similar for oleic and stearic
acid plasma levels in AD patients recently reported in a longitudinal population-based study by
Ronnema et al. (2012) [29]. It is interesting to note that only oleic acid was found to be significantly
elevated when Control was paired with Severe AD (Figure 2). Another study reported similar finding,
but uniquely in the white brain matter of AD patients [17].
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Omega-3 and -6 (n-3/n-6) fatty acids are referred to as essential fatty acids. synthesized from
dietary linolenic or linoleic acids through series of saturation and elongation reactions [30]. Both n-3
and n-6 fatty acids have been implicated in the modulation of brain inflammatory processes [30–32].
Fatty acids, such as arachidonic acid (AA), eicosapentanoic acid (EPA; C20:5), and DHA are thought
to modulate the severity and duration of AD inflammatory processes [33,34]. These fatty acids exert
their inflammatory function through their conversion to potent eicosanoids, such as prostaglandins,
thromboxanes, and leukotrienes (by AA), or resolvins and docosatrienes (by EPA and DHA) by means
of cyclooxygenase (COX) and/or lipoxygenase (LOX) enzymes [29,35].
In the present study, DHA did not differ between any of the 4 groups, a finding which is consistent
with several previous studies [16,17,36]. Other reports, on the other hand, showed lower levels
in AD brain subjects [13,19,21,22,37]. Snowden and colleagues found DHA levels in individuals
with significant AD neuropathology to be unchanged in both the inferior temporal gyrus and the
cerebellum, but it was elevated in middle frontal gyrus [38]. For linolenic acid (a precursor of
DHA as well as EPA) however, we did detect higher levels in moderate AD. Linolenic acid is an
omega-3 FA with anti-inflammatory activity [37,38]. The elevated linolenic acid (in moderate AD)
observed, here, may constitute an anti-inflammatory to the development of early AD disease pathology.
Interestingly, arachidonic acid was higher in moderate AD. Eicosanoids derived from arachidonic acid
are typically pro-inflammatory agents. It has been demonstrated that arachidonic acid is converted
by the enzymatic activity of COX and LOX on increased levels of pro-inflammatory cytokines and
activation of neutrophils, resulting from eicosanoid biosynthesis from enzymatic activity of COX and
LOX on arachidonic acid [39]. Our study showed decreased levels of both linolenic acid and arachidonic
acid (Figure 2). While the reason for such occurrences in the brain are yet to be fully determined, the
trend, however, was found to be in keeping with plasma levels of recently studied AD patients [40].
The decreasing trend of AA and LA seen in plasma AD patients was indicative of a deficiency in
neuroprotective elements against the pathology of the disease, and the excessive inflammation that
was occurring [40]. Furthermore, the significantly higher cis-13,16-docosadienoic concentrations in
moderate AD group could form part of an anti-inflammatory response to the development of AD.
Higher levels of cis-13,16-docosadienoic concentrations could provide neuroprotection by blockading
COX enzyme activity [34]. The overlapping levels of fatty acids seen and described earlier in
age-matched Controls with moderate and severe AD subjects, provide a unique profile which may
serve as indicating potential biomarkers of the disease.
Dementia with Lewy bodies (DLB) is the second major type of senile, degenerative dementia after
AD. It is characterized by the presence of cytoplasmic inclusions of highly conserved amyloidogenic
α-synuclein [41] protein that mirrors tau proteins in AD. It is localized, in part, to presynaptic terminals
where it loosely associates with synaptic vesicles [42,43]. Numerous studies have been conducted on
its structural organization at various stages of fibrillation and inclusion formation.
Fatty acids have been found to play an important role in the conversion of normal, soluble
α-synuclein to insoluble and potentially cytotoxic forms. In vitro studies of mouse embryonic stem
cells (MES) neurons showed PUFA promotes the appearance of oligomeric forms of α-synuclein in
a time-dependent manner [44], while increasing the degree of unsaturation of fatty acids strikingly
enhanced the amount of soluble forms [44]. It is further noted that higher levels of α-synuclein in DLB
brains may be linked to the changes in the composition of endogenous brain fatty acid species. Sharon
et al. (2003) reported a consistently lower linolenic acid and higher DHA levels in frontal cortex of
DLB brains [45]. In contrast to their findings, our results indicate higher concentrations of linolenic
acid when DLB are either paired with Control or severe AD groups (Figure 2; Table 2).
In addition, the study also found no changes or significant alterations in arachidonic acid levels,
as well as other MUFAs [45]. We, however, saw higher concentrations of such species in both
Control, and few in severe AD-paired groups. Furthermore, the higher abundance of saturated fatty
acids, including palmitic acid, stearic acid, behenic acid, and lignoceric acid, observed in our study,
may suggest a protective mechanism by counterbalancing the oligomeric formation of α-synuclein
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by eicosatrienoic, linolenic, and arachidonic acid in DLB brains (Figure 2; Table 2). One study
demonstrated the impact of DHA and arachidonic acids imposing conformational changes in the
structure of α-synuclein, whereas the action of palmitic and arachidic acids remained unchanged [46].
To the best of the author’s knowledge, this is the first study that directly compares brain fatty acid
profiles of Alzheimer’s disease and DLB. Despite the fact that the overlapping FA species between
severe AD and Control with DLB are relatively unknown, with regards to their individual function,
it still highlights the probability of such fatty acids being used as potential biomarkers to distinguish
the differences between these groups. Principal component acids in both healthy control, moderate,
and severe AD groups could serve as potential biomarkers that warranted further functional studies.
Particular attention, in future, should be paid to controlling the controlling of post-mortem delay. While
most FAs mentioned above played intrinsic roles in the inflammatory/anti-inflammatory processes of
AD, some remained to be understood, given the discrepancies and limited data available in the current
literature. The FA profiles of AD and DLB are very similar, perhaps reflecting common progression of
the disease, but conclusions such as this require additional studies. This paper provides an insight into
the changes of FA metabolism in the development of AD, as well differences that can be observed in
the profiles of DLB subjects.
4. Materials and Methods
4.1. Reagents and Analytical Standards
The following fatty acid and fatty acid methyl ester standards were purchased from Sigma Aldrich
(Gillingham, Dorset, UK): tricosanoic acid (C23:0), behenic acid (C22:0), cis-11,14-eicosadienoic acid
(C20:2 ∆11,14), heptadecanoic acid (C17:0), cis-10-pentadecanoic acid (C15:1∆10), pentadecanoic acid
methyl ester (C15:0) (PDA), palmitic acid methyl ester (C16:0), palmitoleic acid methyl ester (C16:1∆9),
cis-10-heptadecanoic acid methyl ester (C17:1∆10), stearic acid methyl ester (C18:0), elaidic acid methyl
ester (t-C18:1∆9), oleic acid methyl ester (C18:1∆9), linolelaidic acid methyl ester (t-C18:2 ∆9, 12)
linoleic acid methyl ester (C18:2 ∆9,12), arachidic acid methyl ester (C20:0), linolenic acid methyl ester
(C18:3 ∆9,12,15), heneicosanoic acid methyl ester (C21:0), all-cis-11,14,17-eicosatrienoic acid methyl
ester (C20:3 ∆11,14,17), arachidonic acid methyl ester (C20:4 ∆5,8,11,14), all-cis-13,16-docosadienoic
acid methyl ester (C22:2 ∆13,16), lignoceric acid methyl ester (C24:0), nervonic acid methyl ester (C21:1
∆15), docosahexanoic acid methyl ester (C22:6 ∆4,7,10,13,16,19) (DHA), all-cis-8,11,14-eicosaterinoic
acid methyl ester (C20:3 ∆8,11,14), erucic acid methyl ester (C22:1 ∆13). All solvents used (methanol
n-hexane and dichloromethane) were CHROMASOLV HPLC grade (Sigma Aldrich, UK). Hydrogen
chloride (1.25 M) in methanol was purchased from Fluka Analytical (UK).
4.2. Human Post-Mortem Tissue
As previously described by Graham et al. (2014) [47], post-mortem tissue samples (parietal
neocortex, Brodmann area 7) were obtained from pathologically and clinically confirmed cases of AD
(n = 46), DLB (n = 14), and normal age-matched controls (n = 27) [47] (Table S1). The parietal cortex
(Brodmann 7) region was selected as it not the primary site of AD pathology. Studies have shown
that FA composition of the parietal cortex is less affected than other brain regions, such as the frontal
or temporal cortex [16]. The AD was classified as moderate (“intermediate” AD neuropathological
change [48], and also Braak tangle stage III–IV; n = 16) or severe (“high” AD neuropathological
change [48], and also Braak tangle stage V–VI; n = 30). Mixed pathology cases were excluded from the
study. Cases were geographically spread across the United Kingdom (Bristol, Newcastle, and London)
and were obtained through the Brains for Dementia Research (BDR; see acknowledgements). Sample
selection did not control for post-mortem delay, and there was a significantly difference between
Severe AD and Moderate AD (p = 0.03). The neuropathological diagnoses were made using widely
accepted criteria [48,49], uniformly applied according to a standardized protocol by members of the
BDR Neuropathology Group. DLB was diagnosed on the basis that (i) there was a clinical diagnosis
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of dementia, (ii) some Lewy bodies were present in the neocortex [50]. Consent and ethical approval
for the use of tissue were obtained by individual brain banks, all of which are licensed by the Human
Tissue Authority (UK). Consent and ethical approval for the use of tissue was obtained by individual
brain banks, all of which are licensed by the Human Tissue Authority. The study was conducted in
accordance with the Declaration of Helsinki, and the protocol was reviewed by the School Research
Ethics Committee (Biological Sciences, Queen’s University Belfast) (0512-GrahamS).
4.3. Sample Preparation and GC-MS Analysis
Frozen tissue samples stored at −80 ◦C were initially lyophilized by placing them in a freeze-drier
at −50 ◦C. Following the complete removal of moisture tissue specimens, they were placed into a
cryogenic grinder (Model 6850, SPEX SamplePREP, UK), which uses liquid nitrogen as a coolant
throughout the milling process and, thus, avoids heat generation which could affect the concentration
of metabolites in the brain tissue samples. Once milled, all samples were stored at −80 ◦C. Lipids were
extracted from tissue by the Folch extraction method [51]. Briefly, 50 mg of powder (weighed out into
sterile Eppendorf tubes (2 mL) chilled on ice). Methanol/water (50% v/v; 1 mL) was added to each
sample and shaken for 10 min using a Minimix Standard Shaker (Merris Engineering, Maidenhead,
Berkshire). Samples were then sonicated for 15 min. Protein was removed by centrifugation at
16,000× g at 4 ◦C for 20 min. To assess the recoveries of FA species, lauric acid (C12:0) was selected
as an internal standard, as it was found to be completely absent in all the post-mortem human brain
samples. Lauric acid was added to each sample pellet (100 ng/µL) and FAs were extracted in 1 mL of
DCM, transferred to sterile test tubes, and evaporated to dryness under nitrogen. FAs were derivatized
to fatty acid methyl esters (FAMEs) by reconstituting the dried extracts in 2 mL hydrogen chloride
in methanol. Samples were subsequently cooled, and 1 mL of water was added. The FAMEs were
extracted in 1 mL of hexane and subsequently analyzed using an Agilent GC (model 7890, Wilmington,
DE, USA) coupled to an MS detector (Agilent model 5975C, Wilmington, DE, USA). The FAMEs
procedure creates methyl esters from free fatty acids, but also from esterified fatty acids and, therefore,
measurements reflect the total levels of unesterified and esterified fatty acids.
Samples were injected (inlet temp 220 ◦C, split-mode ration of 15:1) onto a CP-Sil88 fused silica
capillary column (100 m × 0.25 mm × 0.25 5 µm) (Agilent, UK) with helium as the carrier gas at a
constant flow of 1 mL/min. The initial temperature gradient began at 100 ◦C, increasing at 4 ◦C/min
to 220 ◦C/min, and held for 5 min. Following this, the gradient increased at 4 ◦C/min to 240 ◦C/min,
and was held for 8 min. The mass selective detector (MSD) operated at 70 eV in dual scan/single ion
monitoring (SIM) mode; source temp 230 ◦C, quad temp 150 ◦C and the interface temp 225 ◦C. The full
scan ranged from m/z 50 to 550, whilst SIM mode targeted the molecular ion and another appropriate
ion selected from the fragmentation pattern, each ion having a dwell time of 100 ms. All FAMEs
were confirmed using purchased analytical-grade standards. Quantification was based on a linear
regression model formed from a five-point calibration curve from the individual FAMEs, which were
acquired at a low (0–20 ng/mL) or high concentration range (0–300 ng/mL). FFA concentrations are
reported as g/kg post-mortem human brain dry weight, and corrected to the internal standard. Fatty
acids with calibration curves (n = 3) of poor linearity of (R2 < 0.9) were not quantified
4.4. Data Analysis
Normality of distribution was assessed using the Anderson–Darling test. Nonparametric methods
were used since the assumption that FA concentrations were normally distributed was not satisfied
for many variables. The four groups were compared on metabolite levels using Kruskal–Wallis tests.
Elaidic and cis-10-pentadeconaic acid were excluded, given the large prevalence of values of 0. Given
the large number of variables tested, false discovery rates were computed based on the p-values
from the Kruskal–Wallis tests on the remaining 24 variables. Multiple comparison procedures using
stepdown permutation p-values, on the ranked data, were used to investigate group differences
for variables with a false discovery rate of 0.05 or less. Statistical analysis used the SAS System
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for Windows version 9.3 (Cary, NC, USA). All tests were two-sided, and p < 0.05 was considered
statistically significant. Graphical representations of the data were produced using Prism (GraphPad
5.0, La Jolla, CA, USA). Group comparisons of patient characteristics (age, % female, and post-mortem
delay) were compared by parametric one-way ANOVA. Associations between FAs and continuous
variables (age, post-mortem delay, beta-amyloid, or tau) were tested by Spearman’s rank correlation
coefficient. The relationship between FA levels and gender were carried out by dividing subjects into
male and female and conducting a Mann–Whitney U t-test for each FA. PCA was completed using
Simca P (v14.1; Umetrics, Umea, Sweden) using mean centered and log transformed data.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-1989/8/4/69/s1,
Table S1: Descriptive characteristics of the study population by group, Table S2: Aggregated fatty acid
concentrations and ratios, Table S3: Associations between fatty acids and clinical variables (age, gender,
post-mortem delay, frontal tissue pH, beta-amyloid, tau); Figure S1. Principal component analysis (PCA) of fatty
acid concentrations in post-mortem human brain specimens.
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